Table 4.

Effect of biologic therapy on disease activity

ILAR subtype	SJIA	OJIA	RF− PJIA	RF+ PJIA	ERA	JPsA	Subtype unknown	Total	P
Number of patients	11	38	19	36	24	26	71	225
Baseline DAS28a	5.8 (4.4–7.0)	6.3 (5.4–7.5)	6.6 (5.3–7.0)	6.4 (5.9–7.2)	5.9 (4.9–6.7)	6.3 (5.4–7.0)	6.5 (5.7–7.1)	6.3 (5.4–7.1)	0.62
6-month DAS28b	4.9 (2.6–5.6)	3.7 (3.0–4.5)	4.0 (3.0–5.3)	4.0 (3.2–5.0)	3.0 (1.6–4.8)	3.3 (2.6–4.1)	3.8 (2.6–5.2)	3.8 (2.7–4.9)	0.36
6-month EULAR response, %
None	37.5	22	18	22	10	25	20	21
Moderate	37.5	47	47	59	30	37.5	43	46	0.58
Good	25	31	35	19	60	37.5	37	33
Percentage DAS28 remission, 6 months	25	16	18	13	31	25	26	21	0.71
12-month DAS28c	2.9 (1.9–5.1)	4.0 (2.9–4.9)	4.3 (2.5–5.0)	4.5 (2.9–5.4)	2.0 (1.2–4.7)	2.6 (2.4–4.4)	3.7 (2.8–5.6)	3.7 (2.5–5.2)	0.10
12-month EULAR response, %
None	28.5	11.5	27	30	11	28	18	22
Moderate	28.5	61.5	33	47	33	33	54	46	0.48
Good	43	27	40	23	56	39	28	32
Percentage DAS28 remission, 12 months	29	19	27	20	58	50	21	28	0.055

All values median (IQR) or n (%). SJIA: systemic onset JIA; OJIA: oligoarticular JIA; RF− PJIA: RF-negative polyarticular JIA; RF+ PJIA: RF-positive polyarticular JIA; PJIA: psoriatic JIA; UnJIA: unclassifiable JI. ^aNumber of patients with DAS28 available at baseline: 204/225 (91%). ^bNumber of patients with DAS28 available at 6 months: 172/225 (76%). ^cNumber of patients with DAS28 available at 12 months: 151/225 (67%).